A DRUG said to cure diabetes could mean that sufferers will no longer need to take daily insulin injections.
The treatment uses stem cells made from human bone marrow and has been tested on patients suffering from Type 1 diabetes – which affects about 900,000 people in Britain.
Diabetes causes the immune system to attack the pancreas, the organ that makes insulin, which then controls blood-sugar levels.
Sufferers must take insulin injections to stay alive because if blood-sugar levels are allowed to rise too high or get too low, they could fall into a coma and die.
But early trials by American scientists
Image via Wikipedia
Before going ahead and explaining the possibilities that are on the verge of development based on the regenerative capabilities of a stem cell, let us first understand what a stem cell is actually. Stem cells are the basic group of cells that have the extremely potent capability of regenerating themselves. The process through which they regenerate themselves is known as mitotic cell division and after the division, the previously unspecialized cells turn into specialized cells for specific organs through cellular differentiation.
These cells are not found in unicellular organisms, but are found in varying quantities within all multi
OKLAHOMA CITY — The debate over stem cell research stirs up deeply held religious, moral and ethical views.
But some aren’t sure what a possible ban or veto will mean for Oklahoma.
Cells tinier than a pin head have some asking larger-than-life questions.
House Bill 1326 would criminalize research that would destroy or cause substantial risk to a human embryo.
The Oklahoma Medical Research Foundation reports this type of research isn’t even happening in the state right now.
The foundation is doing research on adult stem cells but not embryonic.
But its workers say no one knows what the medical landscape will look like in
Cellular Dynamics International, Inc. (CDI), the world’s largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell™ Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells).
“CDI’s mission is to be the top developer and manufacturer of standardized human cells in high quantity, quality and purity and to make these cells widely available to the research community. Our MyCell Services provide researchers with unprecedented access to the full diversity
In a ray of hope for millions of leukaemia patients, American scientists have claimed to have developed a technique which multiplies the small number of stem cells in the donor blood, making it much more potent for the treatment of the fatal disease.
It also eliminates the need for a matching donor, whose bone marrow is usually transplanted to the patient, according to a study which appeared in the journal Nature Medicine. Traditionally, there was always a risk that the patient’s body may reject the new cells from a donor.